Stockscreener 앱 받기
0.33%
시간 외 거래:
Pfizer Inc 주식(PFE)의 최신 뉴스
Atopic Dermatitis Pipeline 2026: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | GlaxoSmithKline PLC, Nestle SA, Pfizer Inc., Regeneron Pharma, Abbvie - Barchart.com
Pfizer vs Moderna 2026: Pipeline Prospects After Vaccine Sales DropNews and Statistics - IndexBox
Pfizer vs Moderna: Which Pharma Stock Has More Upside? - The Globe and Mail
Pfizer vs Moderna: Which Pharma Stock Has More Upside? - The Motley Fool
Does Positive TALAPRO‑3 and FOURLIGHT‑1 Data Reframe Pfizer’s Oncology Story And Investment Case (PFE)? - simplywall.st
Pfizer to seek earlier indication for Talzenna combo - The Pharma Letter
Pfizer aims for wider use of PARP drug in prostate cancer with new data - BioPharma Dive
Why Is Pfizer Stock Gaining Thursday?Pfizer (NYSE:PFE) - Benzinga
Self-represented worker ordered to pay $10K after abandoning motion to disqualify Pfizer’s counsel - HR Law Canada
Pfizer Among World’s Most Ethical Companies for 5th Straight Year - Pfizer
Pfizer (PFE) Achieves Key Milestone with Prostate Cancer Drug Tr - GuruFocus
Swiss Life Asset Management Ltd Decreases Position in Pfizer Inc. $PFE - MarketBeat
Pfizer Reports Positive Results in Prostate Cancer Study - marketscreener.com
Pfizer posts late-stage trial win for Talzenna plus Xtandi in new prostate cancer indication - Seeking Alpha
Wilmington Savings Fund Society FSB Sells 75,143 Shares of Pfizer Inc. $PFE - MarketBeat
Analysts Offer Insights on Healthcare Companies: Conmed (CNMD), Alto Neuroscience, Inc. (ANRO) and Pfizer (PFE) - The Globe and Mail
CIBC Bancorp USA Inc. Invests $20.07 Million in Pfizer Inc. $PFE - MarketBeat
AIA Group Ltd Has $12.31 Million Stock Holdings in Pfizer Inc. $PFE - MarketBeat
Achmea Investment Management B.V. Acquires 201,826 Shares of Pfizer Inc. $PFE - MarketBeat
Pfizer's Oncology Pipeline Gains Momentum with Promising Breast Cancer Trial Data - AD HOC NEWS
Reassessing Pfizer (PFE) Valuation As Shares Trade Around Recent Levels - Yahoo Finance
Pfizer (NYSE:PFE) Enhances Value Proposition Across Russell 1000 Healthcare Sector - Kalkine Media
Pfizer Advances Early PF-07328948 Liver Study, Adding Quiet Support to PFE’s Pipeline Story - TipRanks
Pfizer Ends Early-Stage Melanoma Study, Trimming One Oncology Bet But Not the Broader Pipeline - TipRanks
Pharma Stocks Analysis 2026: Pfizer & Novo Nordisk Rebound, Exelixis GrowthNews and Statistics - IndexBox
Lucid Group Appoints Former Pfizer R&D Leader Rod MacKenzie, CMG, PhD, as Board Chair to Drive Next Phase of Global Growth and Innovation - PR Newswire
Pfizer Inc (NYSE:PFE) Moves with S&P 500 Amid Pipeline Updates - Kalkine Media
Pfizer: I'm Still Expecting A Massive Rebound (NYSE:PFE) - Seeking Alpha
Pfizer Phase 2 Wins Reshape Growth Story In Oncology And Immunology - simplywall.st
Danske Bank A S Acquires Shares of 3,190,647 Pfizer Inc. $PFE - MarketBeat
Morgan Stanley Maintains Positive on Pfizer Inc. (PFE) March 2026 - Meyka
Captrust Financial Advisors Cuts Stake in Pfizer Inc. $PFE - MarketBeat
Pfizer, Roche Looking Beyond Simple Licensing In China Deals - Citeline News & Insights
Jim Cramer Notes Pfizer (PFE) Has “Got a Lot of Stuff in the Pipeline” - Insider Monkey
Pfizer (NYSE:PFE) Trading 3.2% Higher Following Analyst Upgrade - MarketBeat
Pfizer Finds Lucky Clover In Phase II Atirmociclib Trial - Citeline News & Insights
Pfizer Reports Positive Mid-Stage Breast Cancer Trial Results - GuruFocus
Pfizer Inc Stock (PFE) Moved Up by 3.89% on Mar 17: What Investors Need To Know - TradingKey
+3.04% for Pfizer stock — Strong R&D focus and positive drug news lift shares - Traders Union
What triggered Pfizer shares' latest price surge - Traders Union
HSBC Maintains Buy Rating on Pfizer (PFE) with Raised Price Targ - GuruFocus
Pfizer Reports Positive Phase 2 Results for Breast Cancer Treatment Candidate - geneonline.com
Pfizer’s Ibrance successor moves forward with new study data - BioPharma Dive
Pfizer Touts Promising Survival Data Without Worsening For Advanced Breast Cancer Patients - Benzinga
Morgan Stanley reiterates Pfizer stock rating on positive trial data - Investing.com
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Narcissu Market Set for Dynamic Boom as Key Players Pfizer • Johnson & Johnson • Merck & Co. • Amgen - openPR.com
Pfizer (PFE) Reports Positive Mid-Stage Trial Results for Breast Cancer Therapy - GuruFocus
Pfizer says experimental breast cancer drug cuts risk of disease worsening in mid-stage trial - marketscreener.com
National Bank of Canada FI Decreases Stake in Pfizer Inc. $PFE - MarketBeat
Pfizer (PFE) Reveals Promising Phase 2 Study Results for Atirmoc - GuruFocus
Pfizer Inc. Announces Positive Topline Phase 2 Results for Next-Generation CDK4 Inhibitor, Atirmociclib in Second-Line Metastatic Breast Cancer - marketscreener.com
Pfizer posts mid-stage trial win for breast cancer drug (PFE) - Seeking Alpha
Federal Judge Flags Legal Flaws In RFK Jr.'s Vaccine Overhaul - Benzinga
Pfizer’s atirmociclib shows 40% reduction in cancer progression risk By Investing.com - Investing.com India
Pfizer Inc Stock (ISIN: US7170811035) Trades Steadily Amid Valuation Appeal and Dividend Strength on - AD HOC NEWS
Pfizer Announces Positive Topline Phase 2 Results for Next-Generation CDK4 Inhibitor, Atirmociclib, in Second-Line Metastatic Breast Cancer - Business Wire
HSBC Adjusts Price Target on Pfizer to $32 From $29, Maintains Buy Rating - marketscreener.com
Jain Global LLC Boosts Stake in Pfizer Inc. $PFE - MarketBeat
IP Group shares jump 8% as Pfizer obesity deal drives 13% NAV gain in 2025 - Investing.com UK
Focus Partners Wealth Acquires 551,274 Shares of Pfizer Inc. $PFE - MarketBeat
IP Group CEO on 2025 highlights, NAV uplift, Pfizer royalties & capital allocation - Proactive Investors
IP Group returns to growth as Pfizer deal drives NAV rise - Yahoo Finance UK
IP Group returns to profit as Pfizer deal and tech exits lift NAV and fund buybacks - TipRanks
Alliancebernstein L.P. Has $170.30 Million Stake in Pfizer Inc. $PFE - MarketBeat
Marine Drug Market: Ready To Fly on high Growth Trends | Pfizer, AstraZeneca, Amgen - openPR.com
Oncology Drugs Market Is Booming So Rapidly | Pfizer Inc., Novartis AG, AstraZeneca PLC - openPR.com
Should You Avoid Pfizer? Here's the Key Risk to Watch - Yahoo Finance
0.99%
자본화:
|
볼륨(24시간):